Author:
Singh Dave,Donohue James F.,Boucot Isabelle H.,Barnes Neil C.,Compton Chris,Martinez Fernando J.
Abstract
Most patients with COPD are recommended to initiate maintenance therapy with a single long-acting bronchodilator, such as a long-acting muscarinic antagonist or long-acting β2-agonist. However, many patients receiving mono-bronchodilation continue to experience high symptom burden, suggesting that patients are frequently not receiving optimal treatment. Treatment goals for COPD are often broad and not individually tailored, making initial treatment response assessments difficult. A personalised approach to initial maintenance therapy, based upon an individual's symptom burden and exacerbation risk, may be more appropriate.An alternative approach would be to maximise bronchodilation early in the disease course of all patients with COPD. Evidence suggests that dual bronchodilation has greater and consistent efficacy for lung function and symptoms than mono-bronchodilation, whilst potentially reducing the risk of exacerbations and disease deterioration, with a similar safety profile to mono-bronchodilators. Improvements in lung function and symptoms between dual- and mono-bronchodilation have also been demonstrated in maintenance-naïve patients, who are most likely to resemble those at first presentation in a clinical setting. Despite promising results, there are several evidence gaps that need to be addressed to allow decision makers to evaluate the merits of a widespread earlier introduction of dual bronchodilation.
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Reference105 articles.
1. Global and regional estimates of COPD prevalence: systematic review and meta-analysis;Adeloye;J Glob Health,2015
2. Global initiative for Chronic Obstructive Pulmonary Disease (GOLD) . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2021 report). www.goldcopd.org/2021-gold-reports Date last accessed: 16 November 2020. Date last updated: November 2020.
3. Global initiative for Asthma (GINA) . Global strategy for asthma management and prevention. www.ginasthma.org/gina-reports Date last accessed: 16 November 2020. Date last updated: April 2020.
4. COPD control: can a consensus be found?;Guimarães;Revista Portuguesa de Pneumologia (English Edition),2016
5. Validation of clinical control in COPD as a new tool for optimizing treatment;Soler-Cataluña;Int J Chron Obstruct Pulmon Dis,2018
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献